Premium
Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies
Author(s) -
Cheng Qingyu,
Pelz Andreas,
Taddeo Adriano,
Khodadadi Laleh,
Klotsche Jens,
Hoyer Bimba F.,
Alexander Tobias,
Thiel Andreas,
Burmester GerdR.,
Radbruch Andreas,
Hiepe Falk
Publication year - 2020
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.201948144
Subject(s) - antibody , biology , in vivo , secretion , antigen , immunology , humoral immunity , population , plasma cell , immune system , microbiology and biotechnology , endocrinology , medicine , environmental health
Abstract Antibody‐mediated diseases affect more than 10% of the human population. For most, no cure is available, particularly when the pathogenic antibodies are secreted by long‐lived plasma cells resistant to conventional immunosuppressive therapies. Current therapeutic approaches target not only the plasma cells that secrete pathogenic antibodies, but also those providing protective antibodies. Here, in a murine model bearing long‐lived plasma cells secreting anti‐OVA and ‐chicken gamma globulin (CGG) antibodies, we describe the first‐time use of an antigen‐antibody (OVA/anti‐CD138 antibody) conjugate for in vivo labeling and selective ablation of plasma cells that secrete antibodies specific for the antigen OVA. The selective depletion also led to a stable reduction of the corresponding serum anti‐OVA antibody levels. In contrast, CGG‐specific plasma cells and circulating anti‐CGG antibody levels remained unchanged. The method described here should enable the development of unique causative treatment strategies for established antibody‐mediated diseases sparing humoral immunity.